Knight Book Value Per Share from 2010 to 2024

GUD Stock  CAD 5.48  0.02  0.37%   
Knight Therapeutics Book Value Per Share yearly trend continues to be very stable with very little volatility. Book Value Per Share is likely to drop to 5.14. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Knight Therapeutics according to its financial statements. View All Fundamentals
 
Book Value Per Share  
First Reported
2010-12-31
Previous Quarter
6.94983672
Current Value
5.14
Quarterly Volatility
3.24919213
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Knight Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Knight Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 75.6 M, Interest Expense of 9.4 M or Selling General Administrative of 87.9 M, as well as many indicators such as Price To Sales Ratio of 1.61, Dividend Yield of 0.5 or PTB Ratio of 0.71. Knight financial statements analysis is a perfect complement when working with Knight Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Knight Therapeutics Technical models . Check out the analysis of Knight Therapeutics Correlation against competitors.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Other Information on Investing in Knight Stock

Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.